C₂N's scientific advisors are world-class authorities in neurodegenerative disease, Alzheimer’s pathophysiology, clinical medicine, and pharmaceuticals and diagnostic biomarkers development.

David Holtzman, MD
Scientific Co-Founder

Along with Dr. Bateman (below), Dr. Holtzman is a Scientific Co-Founding Member of C₂N Diagnostics. Dr. Holtzman is the Andrew B. and Gretchen P. Jones Professor of Neurology and Molecular Biology & Pharmacology at the Washington University School of Medicine. He is also head of Washington University’s Department of Neurology, the Associate Director of the institution’s Alzheimer's Disease Research Center, and a member of the Hope Center for Neurological Disorders. A major focus of Dr. Holtzman’s research is in understanding basic mechanisms underlying acute and chronic cell dysfunction in the CNS, particularly as these mechanisms may relate to Alzheimer’s Disease and injury to the developing brain. Dr. Holtzman attended the Honors Program in Medical Education at Northwestern University receiving his B.S. (1983) and M.D. (1985). He completed his medical internship followed by Neurology residency at UCSF from 1985-1989. He then pursued post-doctoral research training in the lab of William C. Mobley, MD, PhD, at UCSF from 1989-1994. Also at UCSF, Dr. Holtzman established the Memory and Cognitive Disorders Clinic and was an Assistant Professor from 1991-1994. He moved to his own laboratory at Washington University in December of 1994. He was named as the Associate Professor of Neurology in 2001, Professor in November of 2002, and as the Andrew and Gretchen Jones Professor and Head of the Department of Neurology in October 2003. In addition, to his laboratory, administrative, and teaching duties, Dr. Holtzman is involved in clinical and research activities at the Washington University Alzheimer's Disease Research Center. Past honors include being the recipient of a Paul Beeson Physician Faculty Scholar Award in Aging Research, the 2003 Potamkin Prize from the American Academy of Neurology for research on Alzheimer's, election to the American Society for Clinical Investigation (2004), a MERIT award from the NIA (2004), and a 2006 recipient of the MetLife award on Alzheimer’s disease.

Randall Bateman, MD
Scientific Co-Founder

Dr. Bateman is also a Scientific Co-Founding Member of C₂N Diagnostics. He is an Assistant Professor of Neurology at the Washington University School of Medicine. Dr. Bateman attended Washington University where he received a B.S. degree in Biology (1995) and a B.S. degree in Electrical Engineering (1995). He attended Case Western Reserve University School of Medicine where he received his M.D. (2000) with special emphasis on the neurosciences. He completed a medical internship (2001) at Barnes-Jewish Hospital followed by Neurology residency (2004) at Washington University. He then completed post-doctoral research training with David M. Holtzman, M.D. as mentor and clinical research fellowship training at the Washington University ADRC. It is within Dr. Holtzman’s laboratory where Dr. Bateman made the pioneering discovery of measuring the metabolism of neurally-derived biomolecules in vivo, which has formed the basis of C2N’s technology and services to commercialize. Dr. Bateman treats patients with dementia at the Memory Diagnostic Center of Washington University. He is the recipient of multiple grants and awards from the NIH and outside agencies. He has received awards for his research including the AAN Foundation Corporate Roundtable Clinical Research Fellowship (2004), an American Neurological Association Plenary Session Speaker (2005), a World Technology Award Nominee for Health and Medicine Associate (2006), Scientific American 50, award for outstanding technological leadership, chosen as one of the top 50 scientific advancements of 2006, and the Kopolow Award (2007).

Harlan M. Krumholz, MD, SM

Dr. Krumholz is the Harold H. Hines Jr. Professor of Medicine (Cardiology), and Professor of Epidemiology and Public Health at Yale University. He is also the Founding Director of Yale-New Haven’s Hospital Center for Outcomes Research and Evaluation (CORE) and Program Director for the Robert Wood Johnson Clinical Scholars Program at Yale. As a recent inductee into the Institute of Medicine (IOM), Dr. Krumholz is one of the leading international figures in the fields of quality improvement and technology effectiveness research. His work has resulted in more than 400 publications, and has influenced the practice of medicine and delivery of health care on multiple levels. Dr. Krumholz has led teams that pioneered innovative methodologies, which allow identification of key success strategies for top-performing health care organizations. These strategies are now disseminated nationally by third-party payors and health care organizations. Working with the Centers for Medicare and Medicaid Services (CMS) and other major institutions, Dr. Krumholz has also led efforts to define quality measures that are now reported publicly, enabling hospital profiling and enhanced patient consumerism. Dr. Krumholz has chaired and sat on many national committees, including those established by CMS, the National Heart, Lung, and Blood Institute (NHLBI), the Joint Commission on the Accreditation of Healthcare Organizations (JCAHO), the National Center for Quality Assurance (NCQA), the American Heart Association and the American College of Cardiology. He is an elected member of the American Society for Clinical Investigation and the Association of American Physicians. He has also received recognition as one of the “Best Doctors in America”.